IN8Bio: Funding, Investors & Team (Oct 2026)
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
IN8Bio has raised $57.2M across 4 funding rounds on record, the most recent an undisclosed round of $20.1M announced in Dec 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
IN8Bio Company Profile and Key Stats
Latest funding round on record: Dec 2025.
IN8Bio Funding Rounds
IN8Bio raised $10.3M in a Post-IPO Equity announced in Aug 2022.
1.3 years later, an undisclosed round of $14.4M was announced in Dec 2023.
10 months later, an undisclosed round of $12.4M was announced in Oct 2024.
1.2 years later, an undisclosed round of $20.1M was announced in Dec 2025.
IN8Bio Founders and Leadership Team
Contact details for the IN8Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →IN8Bio Funding Compared to Other Biotechnology Startups
IN8Bio's latest round of $20.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like IN8Bio in Biotechnology and New York
Companies Similar to IN8Bio
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
IN8Bio Funding FAQs
What does IN8Bio do?
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
How much funding has IN8Bio raised?
IN8Bio has raised $57.2M across 4 rounds on record. The most recent is an undisclosed round of $20.1M announced in Dec 2025.
When did IN8Bio last raise funding?
IN8Bio's most recent funding round on record is an undisclosed round of $20.1M, announced in Dec 2025.
Who is the CEO of IN8Bio?
William Ho is listed as CEO at IN8Bio.
Where is IN8Bio headquartered?
IN8Bio is based in New York, United States.
How many employees does IN8Bio have?
IN8Bio is in the 11-50 employee band.
How does IN8Bio's funding compare to other Biotechnology startups?
IN8Bio's latest round of $20.1M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's IN8Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for IN8Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.